ASH 2020 | DREAMM-6: belamaf-based combination therapy in R/R MM
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, outlines the findings of the Phase I/II DREAMM-6 study (NCT03544281) of a belantamab mafodotin (belamaf)-based combination therapy in relapsed/refractory multiple myeloma patients. Belamaf is an anti-BCMA antibody-drug conjugate, shown to induce deep and durable responses in heavily pretreated myeloma patients as a monotherapy. A preclinical suggestion of synergy with standard of care agents led to the examination of combined belamaf, bortezomib and dexamethasone treatment in Arm B of this study. The trial is ongoing, with promising interim efficacy and safety data endorsing enrollment of a Phase III study of the triplet in comparison to daratumumab, bortezomib and dexamethasone (DREAMM-7). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
